INTRODUCTION
velop into functionally specialized cells. There is much evidence that human peripheral blood contains bone marrow-derived progenitor cells, which have the capac-Infarction or ischemia occurring in the brain or heart is a common cause of clinical illness. Occlusion of ity to differentiate into mature endothelial cells, termed endothelial progenitor cells (EPCs) (75). Certain surface blood flow from the supplying artery leads to ischemia, oxygen deprivation, and associated cell injury to organs. membrane markers, including the endothelial marker vascular endothelial growth factor receptor-2 (VEGFR-The consequences of ischemia depend on the tissue area involved in the occlusion, the presence of collateral cir-2) and the hematopoietic progenitor cell markers CD34 and CD133, are expressed on the surface of EPCs after culation, and the vulnerability of a given tissue to hypoxia (19) . Neurons and myocardial cells undergo irre-vascular trauma (8, 30, 45) . EPCs have the potential to form into new blood vessels (postnatal vasculogenesis) versible damage when deprived of blood supply, and persistent ischemia causes irreversible tissue injury and to repair ischemic injury (8, 52, 87) . This process contrasts with the sprouting of new vessels from existing necrosis. Cell necrosis triggers an inflammatory response and a degradation of the extracellular matrix. However, ones in the area (angiogenesis) to relieve ischemia. Vasculogenesis and angiogenesis are different in many as-the high number of cells with the capacity for proliferation and regeneration in highly differentiated organs, pects. Vasculogenesis begins from the assembling of EPCs and formation of a primary vascular plexus (36) . such as the brain and the heart, means that there is potential for self-renewal in these organs (19) .
In angiogenesis, new vessels are produced from preexisting vessels during which endothelial cells replicate, Stem cells have the capacity to self-renew and de-274 DING ET AL. sprout, and make new lumen (37) . In angiogenesis, peri-express CD133 and c-kit (CD117), whereas CESs do not. HSCs express CD38, but generally do not express cyte detachment is the first step to form the new vessels. Endothelial cell replication and degradation of surround-VE-Cadherin or fibroblast growth factor receptor (FGFR), in contrast to EPCs, which express all three. ing extracellular matrix happen thereafter. Many molecules act as mitogens of endothelial cells, such as vascu-Burger and colleagues proposed the following phenotype for EPCs: CD34 + FGFR + CD38 + VE-Cadherin + c-lar endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and many other proteins whose kit + CD31 + KDR + CD133 + , which is generally compatible with the definitions of several other investigators secretion is induced by ischemia (37, 38) .
EPCs can migrate to the site of blood vessel injury (17,67,119). If necessary, distinction between EPCs and CECs can be made by expression of CD146 on CECs to help repair the damage and differentiate into mature endothelial cells (50,83). Restoration of the endothelial and by CD133 on EPCs (90). Activated CECs may be distinguished by expression of CD105 (endoglin), the lining and maintenance of vascular homeostasis are two of the main functions of EPCs, but EPCs also promote receptor for transforming growth factor-β1, which is a recognized regulator of angiogenesis. Currently, it is ac-vascular growth by releasing factors that act in a paracrine manner to support local angiogenesis and mobilize ceptable to measure the number of circulating EPCs by flow cytometry using the markers CD34, VEGFR-2, and tissue-residing progenitor cells (39, 76, 99) . Therefore, EPCs may restore dysfunctional endothelium by an en-CD133. However, the functional and clonogenic capacity of EPCs need to be evaluated using colony-forming dogenous repair mechanism.
In this article, we summarize the current concepts in unit assays (111). A summary of the different markers to differentiate EPCs (early and late), CECs, and HSCs the biology of EPCs, focusing on their role in ischemic cerebral and cardiovascular disease and their clinical im-is provided in Table 1 . plications.
ENDOTHELIAL PROGENITOR CELL MOBILIZATION IDENTIFYING ENDOTHELIAL PROGENITOR CELLS
Accumulating evidence suggests the existence of a common precursor cell for both blood and endothelial EPCs have several origins such as bone marrow (BM), peripheral blood, and tissue-derived stem cells cells in adult life. This precursor might be the adult equivalent of the hemangioblast that has been identified (15, 71, 77) and are characterized by the expression of cell surface markers CD34, CD133, and VEGFR-2 in embryonic development (21, 69, 96) . Additionally, a population of primitive cells has been described with an (KDR/Flk-1) (6, 42) . Additionally, two types of EPCs (early and late) have been identified sequentially from even larger multipotent differentiation potential: the multipotent adult progenitor cells (MAPCs). These cells the same donors during the culture of total mononuclear cells from human peripheral blood (43) . Therefore, are able to differentiate into mesenchymal cells, and into EPCs have heterogenous cell populations of various origins and different phenotypes that have the ability to Badorff and colleagues found that when EPCs from healthy volunteers and coronary artery disease (CAD) cells with neuroectoderm, endoderm, and visceral meso-states, perhaps using small molecules. EPCs express a wide variety of receptors that may enable them to re-derm characteristics (i.e., endothelial cells) in vitro. These MAPCs, identified in long-term culture of human spond to many chemotactic signals that emanate from brain pathologies. Chemokine and cytokine production adherent bone marrow cells, confirm the existence of primitive cells in adult life (78, 105) . Currently, HSCs is a common feature of many brain lesions, including stroke, which suggests that these factors could be impor-and EPCs for transplantation purposes are generally acquired from mobilized peripheral blood, not bone tant in mediating the responses of stem cells to injuries.
Recent studies have demonstrated that integrin-mediated marrow.
Several growth factors, cytokines, and chemokines adhesion and transmigration are involved in the homing of transplanted EPCs to bone marrow (66) , as well as have been found to mediate mobilization of EPCs. In both animal and human studies, stimulation by the the recruitment of EPCs to sites of angiogenesis (102) . growth factors VEGF, stromal derived factor-1 (SDF-1),
Stromal Cell-Derived Factor-1 (SDF-1) and CXC granulocyte colony-stimulating factor (G-CSF), granulo-Chemokine Receptor-4 (CXCR-4) cyte macrophage colony-stimulating factor (GM-CSF), erythropoietin (EPO), angiopoetin-2, fibroblast growth Mutual, reciprocal SDF-1/CXCR4 interactions between HSCs, EPCs, and bone marrow stromal cells reg-factor, placental growth factor (PlGF), platelet-derived growth factor-CC, stem cell factor (SCF), interleukin ulate human stem cell migration and development, as reviewed comprehensively by Dar and coworkers (23). (IL)-2, IL-3, IL-6, IL-8, and IL-1β, which are all known to mobilize HSCs, have also been shown to result in an
The chemokine SDF-1 (also known as CXCL12) and its receptor CXCR4 are reported to be involved in regula-increased number of EPCs (4, 42, 59) . This conformity between the EPC and the HSC response might reflect tion of migration, survival, and development of multiple cell types, including HSCs, EPCs, and stromal stem cells the common origin of these cells (i.e., hemangioblast), or a common physiological mechanism for the mobiliza-(54). During steady-state homeostasis, CXCR4 is expressed by hematopoietic cells and also by stromal cells, tion of progenitor cells from bone marrow. HSCs and EPCs may show concomitant mobilization due to the which are the main source for SDF-1 in the BM. Stress will increase SDF-1 and CXCR4 levels, which stimulate physiological need of synergistic interactions between these cells in the processes of angiogenesis and vasculo-recruitment of immature and maturing leukocytes from the BM reservoir to damaged organs as part of host de-genesis (42) . In this respect, it is thought that VEGF-A, PlGF, and SDF-1, released by blood platelets and fense and repair mechanisms (1, 49) . Additionally, trafficking of SDF-1 is mediated by CXCR4, expressed by monocytes, activate metalloproteinase-9 (MMP-9), which mediates a joint mobilization of HSCs, EPCs, and other endothelial and various stromal cell types in the BM, but not by hematopoietic cells (23) . Transcytosis of cell types. The interactions between these cells and EPCs, which may contribute to the revascularization functional SDF-1 to the BM also occurs in the stem cellrich endothelium and endosteum regions, regulating process, are illustrated in Figure 1 . Endothelial nitric oxide synthase (eNOS) activity has also been suggested to HSCs, EPCs, and stromal interactions in the stem cell niche. Dynamic expression of SDF-1 and CXCR4 in-account for the mobilization of EPCs in response to injury (56). Impaired mobilization of EPCs from bone duces proliferation of HSCs, EPCs, and mesenchymal progenitors, recruitment of osteoclasts, osteoblasts, neu-marrow was observed in eNOS knockout mice (3). Increased NO availability is required for statin-induced trophils, and other myeloid cells, leading to leukocyte mobilization (23) . In one study, the role of a recipient's mobilization of EPCs (53). EPC mobilization was also inhibited by C-reactive protein (CRP), which interferes EPCs in the repair process was studied using wild-type donor female heart transplanted into male rat abdominal with NO production (106) . NO produced by eNOS also interacted with SDF-1 and the CXCR4 signaling path-cavity (109) . Induced male EPCs migrated into the cardiac allograft and SDF-1 mRNA levels increased signifi-way to induce mobilization and homing of EPCs (116) .
cantly. CXCR4 was also strongly expressed. The authors ENDOTHELIAL PROGENITOR CELL HOMING concluded CXCR4 overexpression enhances vascularization in the damaged myocardium, and that the SDF-Progenitor cells such as EPCs are highly migratory and seem to be attracted to injured brain areas such as 1/CXCR4 axis is important in EPC chemotaxis, homing, engraftment, and retention in damaged myocardium (109) . ischemic regions (2, 20) . While stem cell homing to bone marrow has been widely studied (64) , the molecular ba-
The correlation between platelets and EPC homing has also been discussed. Platelets induce differentiation sis of stem cell pathotropism is not well understood. Further identification of the mechanisms involved would of HSCs or EPCs into foam cells and endothelial cells (24). Platelets could be involved in progenitor cell re-pave the way for the development of treatments to enhance endogenous mobilization of stem cells in disease cruitment and differentiation via specific adhesion re- ceptors such as P-selectin/P-selectin glycoprotein li-veal that β1-integrin is necessary for neuroplasticity after intracerebral stem cell transplantation, possibly gand-1 (PSGL-1) and integrins. This interaction may be the central mechanism for homing of EPCs to vascular through the enhanced angiogenesis by homing of stem cells to ischemic sites (89) . injury sites (24,57). Sphingosine-1-phosphate (S1P) can also influence migration and proliferation of EPCs β2-Integrins also mediate the adhesion and transmigration of EPCs as well as hemopoietic stem/progenitor through the S1P receptor and supports SDF-1-induced migration and BM homing of CD34 + progenitor cells cells in vitro (18, 68) . β2-Integrins are involved in the homing of hematopoietic progenitor cells to sites of is-(108). chemia and are critical for their neovascularization ca-Integrins pacity in vivo (18) . Preactivation of β2-integrins on adult EPCs has been shown to significantly augment the Integrins are heterodimeric transmembrane molecules consisting of α and β subunits that mediate cell adhesion in vivo neovascularization capacity of EPCs, whereas β2 −/− animals display a neovascularization defect in a and migration (22) . Homing of progenitor cells such as EPCs to BM or ischemic tissue may follow the paradigm model of hindlimb ischemia (18) .
Whether β2and β1-integrins play the same cellular of mature leukocytes migrating to inflammatory tissue (61) . We have shown that peripheral blood stem cell role or whether different cell types use distinct mechanisms for homing remains to be determined. Further (PBSC) intracerebral transplantation can significantly improve neurological function following chronic cere-studies are still needed to elucidate whether there is a synergism between other adhesion molecules and their bral ischemia in rats, accompanied by increased local cortical cerebral blood flow and β1-integrin expression counterligands in the multistep recruitment of EPCs to ischemic tissue (62) . Modulation of these integrins may in the ischemic hemisphere (89) . The neurological improvement in this study was blocked by β1-integrin in-provide novel opportunities for treating cerebral and cardiac ischemic disease. hibitor (synthetic RDG peptide) (89). These results re-
ENDOTHELIAL PROGENITOR CELLS
Transplantation of EPCs with autologous harvesting eliminates immunorejection; however, mobilization and
IN MYOCARDIAL INFARCTION
supply remain problems (6) . Therefore, use of cytokines to increase maturation and migration of endogenous Myocardial ischemia and the cellular events that ensue may ultimately result in cardiomyocyte death and EPCs has been investigated. VEGF levels rise in conjunction with increased levels of circulating endothelial a reduction in cardiac performance (65) . The vascular endothelium provides a one-cell-thick barrier for the progenitor cells after myocardial infarction (73) . G-CSF injection therapy induced growth and migration of endo-blood vessels of the body and endothelial breakdown has been implicated in many disease processes, such as thelial progenitor cells from the bone marrow, and subsequent neovascularization of the ischemic tissue (44, atherosclerosis (81). Circulating endothelial progenitor cells contribute to blood vessel formation at ischemic 86,94). Studies in rat models showed that G-CSF could recruit endothelial progenitor cells to sites of myocardial sites and are released into circulation after myocardial infarction (7, 33, 94) . The relation between EPCs and is-ischemia, improve ventricular function, and promote neovascularization (47) . Several studies suggest that NO chemic heart disease is illustrated in Figure 2 . A significant correlation between endothelial function and the production from eNOS is reduced in ischemic heart disease (84, 98, 116) . Nitric oxide is essential for EPC-number of endothelial progenitor cells was found in healthy volunteers, which reflects an increased endothe-induced neovascularization (3,34).
Oxidative stress also plays roles in the initiation and lial turnover by the proliferation and differentiated of EPCs into endothelial cells after endothelial injury (41) .
progression of cardiovascular dysfunction associated with ischemic heart disease (115) . Reactive oxygen spe-Endothelial dysfunction and cardiovascular disease have also been shown to be inversely correlated to levels of cies produced by xanthine oxidase, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, and mi-circulating endothelial progenitor cells (41) . Intravenous injection of human endothelial progenitor cells into rats tochondrial enzymes have been proposed to impair endothelial function by scavenging NO and yielding per-following left anterior descending coronary artery ligation resulted in improved ventricular function, and endo-oxynitrite in patients with ischemic heart disease (115) . EPCs also have a higher expression of antioxidative en-thelial progenitor cell accumulation in areas of infarction and in foci of neovascularization (46) . Additionally, en-zymes, which enable them to resist oxidative stress (25) . Inflammatory stimuli may also induce a rapid release dothelial progenitor cells have shown a higher expression of antioxidative enzymes, such as catalase, glutathi-of EPCs into the circulation in humans (74,114). IL-1β, IL-6, and TNF-α were elevated in heart failure caused one peroxidase, and manganese superoxide dismutase, which allow for increased protection against oxidative by coronary artery disease and hypertension (97) . IL-1β is also able to mobilize EPCs and promote neovasculari-stress (25) . zation through a VEGF-dependent pathway (5). Ele-stroke and peaked after 7 days. Ghani and colleagues also reported a reduction in EPCs in patients with cereb-vated levels of CRP have been associated with endothelial dysfunction in the form of inappropriate vascular rovascular disease, when compared with healthy control subjects (32) . They recruited 88 people who were di-constriction or relaxation, which contribute to the progression and adverse prognosis of myocardial infarction vided into acute stroke, stable ischemic cerebrovascular disease, and control groups. EPC colony counts in each (28, 82, 92) . Human recombinant CRP, at concentrations known to predict adverse vascular outcomes, directly in-well of culture dishes differed significantly between the acute stroke (4.75), stable disease (7.25) , and control hibits EPC differentiation, survival, and function, expression of the key components of angiogenesis, and the groups (15.5). The level of EPCs also significantly correlated with the Framingham coronary risk score (p = response of EPCs to chronic ischemia and additionally induced EPC apoptosis in vitro (106) . This occurs in 0.002). They concluded that the low EPC levels may play a role in the pathophysiology of cerebrovascular part via CRP reducing EPC eNOS expression.
Therapeutically, the reduction of EPC number and disease. In our previous study, we also demonstrated that intracerebral injection of peripheral blood stem cells the decreased functional activity of EPCs in patients with coronary artery disease were improved by 3-hydroxy-(CD34 + ) can enhance angiogenesis via β1-integrin in chronic stroke rats (89) . In this study, CD34 + cells dif-3-methylglutaryl coenzymeA (HMG-CoA) reductase inhibitors (statins), VEGF, erythropoietin (EPO), estrogen, ferentiated into glial cells, neurons, and vascular endothelial cells. At the site of CD34 + cell injection, the ex-and exercise (9, 26, 40, 56, 91, 94) . HMG-CoA reductase inhibitors increased the number and functional activity pression of neurotrophic factors was increased. Finally, the behavior of stroke animals injected with CD34 + cells of EPCs in vitro, in mice, and in patients with stable coronary artery disease (26,59,105). Statin therapy also improved faster than those of control animals. Because stroke is well known to be associated with accelerated reendothelialization after balloon injury by improving mobilization and incorporation of bone mar-endothelial abnormalities, it is reasonable to speculate that CECs are also increased in patients with this condi-row-derived EPCs (107,112). Regulation of EPC number and function was also affected by the lipid-lowering tion, and that CEC levels correlate with other indices of endothelial dysfunction. There have been two studies effect of statin therapy. Statins also increased the expression and activity of eNOS, contributing to increased mo-investigating CEC quantification in stroke. Freestone and coworkers (29) looked at patients with atrial fibrilla-bilization and functional activity of EPCs (55). Several studies have shown that the prosurvival phosphatidyl-tion (AF) and stroke as part of a broader study of CECs in AF. They found higher levels of CECs in patients inositol-3-kinase (PI3K)/Akt pathway may play an important role in endothelial cells and EPCs (10, 51) . Thus, with concurrent AF and a history of stroke than in healthy controls with normal sinus rhythm, and that statins, VEGF, EPO, estrogen, and exercise (shear stress) are well known to augment the PI3K/Akt-path-CECs correlated with von Willebrand factor (vWF). Nadar and colleagues (63) studied 29 patients presenting way (101) . Based on the finding that eNOS is essential for mobilization of bone marrow-derived stem and pro-with stroke and hypertension (but no AF), and compared them with 30 high-risk hypertensive patients and 30 nor-genitor cells (3), these stimuli may increase progenitor cell mobilization by PI3K/Akt-dependent activation of motensive controls. Compared with the other two groups, the patients with acute ischemic stroke had significantly the NOS within the bone marrow stromal cells (101) .
higher numbers of CECs per milliliter in venous blood ENDOTHELIAL PROGENITOR and higher levels of vWF and soluble E-selectin. In ad-CELLS IN STROKE dition, the numbers of CECs correlated with both vWF and soluble E-selectin (16) . Acute ischemic stroke caused by occlusion of a cerebral artery leads to sudden interruption of blood flow to Angiogenesis also occurs in stroke conditions. As ischemic tissue usually depends on collateral blood flow parts of the brain, resulting in loss of neurons, astrocytes, and oligodendrocytes. Despite advances in medi-from newly produced vessels, acceleration of angiogenesis should be of therapeutic value to ischemic disorders. cal and surgical treatment, stroke is still a leading cause of death and disability worldwide (103) , and only a mi-Indeed, therapeutic induction of angiogenesis reduced tissue injury in myocardial and limb ischemia (12, 95) . nority of patients can be rescued by systemic thrombolytic therapy. A growing amount of data suggests that In ischemic stroke, on the other hand, angiogenic factors often increase vascular permeability and thus may dete-EPCs are relevant to vascular homeostasis (41, 100) . Taguchi and coworkers reported that CD34 + cells and riorate tissue damage (60). In order to safely apply therapeutic angiogenesis for ischemic stroke treatment, elu-CD133 + cells, as an EPC-enriched population, provided a marker of cerebrovascular function (93) . They demon-cidating its precise mechanism is mandatory (37) . Upregulation and increased phosphorylation of eNOS strated that circulating EPCs increased after the onset of improves endothelium-dependent vasodilation (35, 48) . tion with proangiogenic cytokines (4,58). In addition, statins have been demonstrated to augment EPC number Clinical and experimental evidence suggests that brain ischemia promotes the formation of new vessels (110) . and function (26), and other factors that affect the function of EPCs (e.g., angiotensin II, glucose, and low-In general, neovascularization can take the from of angiogenesis, arteriogenesis, or postnatal vasculogenesis me-density lipoprotein) are potential drug targets (6) . As EPCs have also been shown to play an important role in diated by mobilization of stem and progenitor cells (80). EPCs may promote vascular repair, neovascularization, endothelial cell regeneration, they may also be of benefit in a range of other vascular disorders. and improve endothelial function (56,94). However, the functional role of EPCs in the formation of vessels, cere-Future Research on EPC Mobilization bral blood flow (CBF), and tissue recovery in the ischemic brain remain to be elucidated (3, 14, 72, 118) . Re-Long-term clinical studies examining drug-mediated cently, increased EPCs and enhanced neovascularization mobilization and functional modification of endogenous through an eNOS-dependant pathway was reported EPCs are not available. One focus of future research (31, 56) . Tissue ischemia-induced eNOS activity is also should be the elucidation of the molecular pathways regcritical for ischemic remodeling and for mobilization of ulating EPC levels and the function and genetic modifistem and progenitor cells, and even upregulates neurocation of EPCs leading to improved functional capacity. genesis in the brain (3, 56, 117) . Several studies have also
The development of pharmacological and genetic stratefound that eNOS improved angiogenesis and cerebral gies for targeting EPCs will be necessary in the future (6) . blood flow in ischemic stroke animals (31, 79, 88) .
CONCLUSION CLINICAL IMPLICATIONS
Endothelial dysfunction, neurohumoral activation, in-AND FUTURE PROSPECTS flammation, and increased oxidative stress may play a EPCs as a Marker of Disease Prognosis and Severity role in the pathophysiology of ischemic heart and cerebral disease. The mechanism of mobilization and hom-A lot of evidence shows that EPCs may be a valuable ing of EPCs is a complex process. EPCs could be a potool for clinical health providers. EPC number and functential pharmaceutical target. Future studies should tion correlates with the risk of cardiovascular and cerebexplore the role of EPCs in ischemic heart and cerebral rovascular disease (32, 41) and EPCs play a role in the disease along with their potential therapeutic roles. process of vasuloprotection (26); EPCs can be used as a marker of vascular function. Two recent studies moni- EPCs could be of benefit to patients with ischemic dis- 
